Swedish-based Karolinska Developmetn AB (KDEV) announced that data from Modus Therapeutics’ Phase 2 study sevuparin failed to show a meaningful benefit in the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD). Modus will now consider future options for the development of sevuparin.
The global Phase 2 study included 144 patients at clinical sites across Europe, the Middle East and the Caribbean. The study compared the intravenously (IV) administered sevuparin with pacebo in patients admitted to the hospital with an acute VOC associated with SCD. The study also assessed several pain-related secondary endpoints.
Sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in a number of diseases.
About Karolinska Development AB
A publicly traded venture, it is a Nordic life sciences investment venture. The company focuses on identifying breakthrough medical innovations that are developed by entrepreneurs and leadership teams. It maintains access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region.